Life Science Accounting Update Conference (life - 2012 san jose)

Venue: Hyatt Santa Clara

Location: San Jose, California, United States

Event Date/Time: May 21, 2012 End Date/Time: May 22, 2012
Report as Spam


Life Science Accounting Update Conference

From health care reform implications to collaboration accounting to valuing R&D, this conference will address the latest developments in key areas. You'll hear from experts at Deloitte, Ernst & Young, PwC, KPMG, life science analysts and your industry counterparts.
Learning Objectives:

* Understand the latest accounting changes in key areas
* Recognize the timelines and key factors affecting the life science industry
* Begin to assess the effects of these standards on your company or clients

Registration Information:

Register Now » Cost $995
Discounts are shown at checkout and still available:
Save $100 if you book at least 45 days in advance
Save another $100 if you are one of first 25 to register
(Both discounts are still available)
You can also register by phone, call (877) 440-0227 or 610 789-3110
or Email questions or to be invoiced to:
Agenda: DAY 1
8:00 8:45 Continental Breakfast and Registration
8:45 10:30 Technical Accounting Update
Update on latest relevant developments, amendments and EITFs
Non-GAAP Measures
Loss contingencies
Financial Statement Presentation
IFRS Joint Project Focus
10:30 10:45 Break
10:45 12:00 Collaboration Accounting
Revenue recognition issues
R&D alliances
Disclosure considerations
12:00 1:00 Lunch
1:00 2:30 Industry Panel: Accounting Issues
Introduction and thumbnail profile
Best practices in applying the onslaught of accounting changes
Obstacles and opportunities
What's on the horizon?
2:30 2:45 Break
2:45 4:00 Tax Issues
Impact of healthcare reform
Tax implications of equity transactions
R&D tax credits
Pitfalls and best practices
4:00 5:30 Revenue Recognition
Latest developments
Resulting changes to sales/operations/IT/accounting policies
Rev Rec for new products
Agenda: DAY 2
8:30 10:30 Regulatory and Legal Update
Healthcare Reform
Financial Regulatory Reform
SEC Enforcement Issues in Life Sciences
SEC Comment Letter Trends
Start-Up considerations
Financial disclosures
10:30 10:45 Break
10:45 12:00 Valuation Issues
Fair value accounting
Industry standards for valuation models
Valuing R&D Projects
Valuation and impairment of intangible assets
12:00 1:00 Lunch
1:00 2:30 Industry Overview Panel: Perpsective of Dealmakers and Analysts
Industry performance overview and deal trends
IPO Process/investment strategies: tapping into the public markets
Earnings outlook for benchmark companies
2:30 2:45 Break
2:45 4:00 Accounting for Financial Instruments
Speakers: Deloitte Financial Instruments Project overview
Classification, measurement and impairment: FASB vs. IASB
Impairment redeliberations
Financial Instruments with characteristics of equity
4:00 4:05 Wrap-Up
Conference speakers include:

Brian Jobe, Deloitte, Partner in Deloitte & Touche LLP's Financial Accounting and Reporting Services practice, and currently leads the practice's efforts related to the Life Sciences industry.
For the past eleven years, Brian has provided accounting policy, transaction structuring, technology, and other consulting services to Fortune 1000 and international companies.

Chip Baird, PTC Therapeutics

Nicole Brookshire, Cooley, Partner with focus on corporate and securities law, with a particular emphasis on representation of public companies.

Prasadh Cadambi, Financial Accounting Standards Board, Practice Fellow

Andreas Chrysostomou, Duff & Phelps, Managing Director and Global Leader of the Integrated Healthcare group with focus on Life Science Industry

John Crowley, Vertex Pharmaceuticals, Senior Director of Accounting

Mark Drozdowski, KPMG, Partner and National Audit Leader for Life Science Industry

Bill Knerr, Ernst & Young, Manager of Life Science Group
Bill is a senior Manager in Ernst & Young's assurance practice. Bill is currently serving a three year rotation as the Life Sciences Sector Resident in Ernst & Young's National Professional Practice Group. In this position, Bill consults with E&Y professionals and Life Sciences clients on accounting, auditing and reporting issues, including complex and innovative transactions. Bill is also responsible for developing thought leadership publications on recent standard setting activity and emerging accounting and financial reporting issues for Life Sciences companies. Prior to moving to New York, Bill served Pharmaceutical and Biotechnology clients in Indianapolis, including Eli Lilly.

Winston Kung, Citigroup, Managing Director with emphasis on pharma and banking

Anthony Torrington, Ernst & Young, Partner and leader in Life Science Practice
Tony is partner in the Assurance practice, with 20 years of experience serving principally high growth life science clients at various stages of development. His technical background focuses on SEC accounting and reporting matters, including filings of registration statements, quarterly and annual reporting on Form 10-Q and Form 10-K, private offering memorandums, acquisition and disposition accounting, revenue recognition matters including, and equity related accounting issues. Tony's current public client responsibilities include Covance, Immunomedics, Delcath Systems, and Aegerion Pharmaceuticals. Tony also served on numerous other public and private companies in the life sciences sector. These companies included Medarex (sold to BMS), Amicus, Genentech, Nekktar, Barrier Therapeutics, Eyetech Pharmaceuticals, Qualitest Pharmaceuticals (sold to Endo), Cardinal Health - Pharmaceuticals and Technologies (now Catalent), Avigen Pharmaceuticals, Axys Pharmaceuticals, ESP Pharma, Esprit Pharma, Sangamo Biosciences, InterMune Pharmaceuticals, MIM Corporation, Titan Pharmaceuticals, and many others.

Andre Van Hoek, Celgene, Corporate VP, Controller and Chief Accounting Officer

PwC Tax Group - Names TBA